Skip to main content

Table 2 Frequencies of the studied SNPs in PD, EOPD and LOPD patients and healthy controls

From: Roles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson’s disease

 

Control group n (%)

PD group n (%)

P

OR (95% CI)

EOPD n (%)

P

OR (95% CI)

LOPD n (%)

P

OR (95% CI)

rs6269 A > G

 AA

56 (35.0)

62 (43.4)

-

-

10 (41.7)

-

-

52 (43.7)

-

-

 AG

77 (49.0)

67 (46.9)

0.33

0.79 (0.48–1.28)

12 (50.0)

0.77

0.87 (0.35–2.16)

55 (46.2)

0.32

0.77 (0.46–1.28)

 GG

24 (15.9)

14 (9.9)

0.09

0.53 (0.25–1.12)

2 (8.3)

0.50

0.47 (0.10–2.29)

12 (10.1)

0.12

0.54 (0.25–1.19)

 AG + GG

101 (65.0)

81 (56.6)

0.17

0.72 (0.46–1.15)

14 (58.3)

0.57

0.78 (0.32–1.86)

67 (56.3)

0.18

0.71 (0.44–1.16)

 Major (A) allele frequency

189 (60.2)

191 (66.8)

-

-

32 (66.7)

-

-

159 (66.8)

-

-

 Minor (G) allele frequency

125 (39.8)

95 (33.2)

0.09

0.75 (0.54–1.05)

16 (33.3)

0.29

0.71 (0.38–1.34)

79 (33.2)

0.11

0.75 (0.53–1.07)

rs4633 C > T

 CC

89 (55.4)

78 (54.6)

-

 

8 (33.3)

-

-

70 (58.8)

-

-

 CT

57 (37.2)

56 (39.2)

0.64

1.12 (0.70–1.81)

15 (62.5)

0.02*

2.93 (1.17–7.35)

41 (34.5)

0.73

0.92 (0.55–1.52)

 TT

11 (7.4)

9 (6.3)

0.89

0.94 (0.37–2.37)

1 (4.2)

1.00

1.01 (0.12–8.87)

8 (6.7)

0.87

0.93 (0.35–2.42)

CT + TT

68 (44.6)

65 (45.5)

0.71

1.09 (0.69–1.72)

16 (66.7)

0.03*

2.68 (1.06–6.47)

49 (41.2)

0.72

0.92 (0.57–1.49)

 Major (C) allele frequency

235 (74.8)

212 (74.1)

-

-

31 (64.6)

-

-

181 (76.1)

-

-

 Minor (T) allele frequency

79 (25.2)

74 (25.9)

0.84

1.04 (0.72–1.50)

17 (35.4)

0.13

1.63 (0.86–3.11)

57 (23.9)

0.75

0.94 (0.63–1.39)

rs4818 C > G

 CC

55 (35.0)

64 (44.8)

-

-

10 (41.7)

-

-

54 (45.4)

-

-

 CG

82 (52.2)

66 (46.2)

0.14

0.69 (0.43–1.12)

12 (50.0)

0.64

0.81 (0.33–1.99)

54 (45.4)

0.12

0.67 (0.40–1.12)

 GG

20 (12.7)

13 (9.1)

0.14

0.56 (0.26–1.23)

2 (8.3)

0.72

0.55 (0.11–2.73)

11 (9.2)

0.17

0.56 (0.25–1.28)

 CG + GG

102 (65.0)

79 (55.3)

0.09

0.67 (0.42–1.06)

14 (58.3)

0.53

0.76 (0.32–1.81)

65 (54.6)

0.08

0.65 (0.40–1.06)

 Major (C) allele frequency

192 (61.2)

194 (67.8)

-

-

32 (66.7)

-

-

162 (68.1)

-

-

 Minor (G) allele frequency

122 (38.9)

92 (32.2)

0.09

0.75 (0.53–1.05)

16 (33.3)

0.46

0.79 (0.41–1.50)

76 (31.9)

0.09

0.74 (0.52–1.05)

rs4680 G > A

 GG

91 (58.0)

79 (55.2)

-

-

8 (33.3)

-

-

71 (59.7)

-

-

 AG

57 (36.3)

56 (39.2)

0.61

1.13 (0.70–1.82)

15 (62.5)

0.02*

2.99 (1.19–7.51)

41 (34.5)

0.75

0.92 (0.56–1.53)

 AA

9 (5.7)

8 (5.6)

0.96

1.02 (0.38–2.78)

1 (4.2)

0.59

1.26 (0.14–11.28)

7 (5.9)

1.00

1.00 (0.35–2.81)

 AG + AA

66 (42.0)

64 (44.8)

0.64

1.12 (0.71–1.77)

16 (66.7)

0.02*

2.76 (1.12–6.82)

48 (40.3)

0.78

0.93 (0.57–1.51)

 Major (G) allele frequency

239 (76.1)

214 (74.8)

-

-

31 (64.6)

-

-

183 (76.9)

-

-

 Minor (A) allele frequency

75 (23. 9)

72 (25.2)

0.71

1.07 (0.74–1.56)

17 (35.4)

0.09

1.75 (0.92–3.33)

55 (23.1)

0.83

0.96 (0.64–1.43)

rs4633 C > T; rs4680 G > A

 CC/GG

86 (54.8)

78 (54.5)

-

-

8 (33.3)

-

-

70 (58.8)

-

-

 Others

71 (45.2)

65 (45.5)

0.97

1.01 (0.64–1.59)

16 (66.7)

0.05

2.42 (0.98–5.99)

49 (41.2)

0.50

0.85 (0.52–1.37)

  CC/GA

3 (1.9)

0

0.25

-

0

1.00

-

0

0.26

-

  CT/GG

4 (2.6)

1 (0.7)

0.37

0.28 (0.03–2.52)

0

1.00

-

1 (0.8)

0.39

0.31 (0.03–2.81)

  CT/GA

53 (33.8)

55 (38.5)

0.59

1.14 (0.70–1.86)

15 (62.5)

0.02*

3.04 (1.21–7.66)

40 (33.6)

0.78

0.93 (0.55–1.56)

  TT/GG

1 (0.6)

0

1.00

-

0

1.00

-

0

1.00

-

  TT/GA

1 (0.6)

1 (0.7)

1.00

1.10 (0.07–17.93)

0

1.00

-

1 (0.8)

1.00

1.23 (0.08–20.00)

  TT/AA

9 (5.7)

8 (5.6)

0.97

0.98 (0.36–2.67)

1 (4.2)

1.00

1.19(0.13–10.67)

7 (5.9)

0.93

0.96 (0.34–2.70)

rs6269 A > G; rs4818 C > G

 AA/CC

52 (33.1)

61 (42.7)

-

-

10 (41.7)

-

-

51 (42.9)

-

-

 Others

105 (66.9)

82 (57.3)

0.09

0.67 (0.42–1.06)

14 (58.3)

0.41

0.69 (0.29–1.67)

68 (57.1)

0.10

0.66 (0.40–1.08)

  AA/CG

4 (2.6)

1 (0.7)

0.19

0.21 (0.02–1.97)

0

1.00

-

1 (0.8)

0.37

0.26 (0.03–2.36)

  AG/CG

76 (48.4)

64 (44.8)

0.19

0.72 (0.44–1.18)

12 (50.0)

0.67

0.82 (0.33–2.04)

52 (43.7)

0.18

0.70 (0.41–1.18)

  AG/CC

1 (0.6)

3 (2.1)

0.63

2.56 (0.26–25.34)

0

1.00

-

3 (2.5)

0.62

3.06 (0.31–30.38)

  GG/CC

2 (1.3)

0

0.22

-

0

1.00

-

0

0.50

-

  GG/CG

2 (1.3)

1 (0.7)

0.60

0.43 (0.04–4.84)

0

1.00

-

1 (0.8)

1.00

0.51 (0.05–5.80)

  GG/GG

20 (12.7)

13 (9.1)

0.14

0.55 (0.25–1.22)

2 (8.3)

0.72

0.52 (0.11–2.58)

11 (9.2)

0.17

0.56 (0.24–1.29)

6269 A > G; rs4633 C > T; rs4818 C > G; rs4680 G > A;

1. L/L

20 (12.7)

29 (20.3)

0.10

0.47 (0.19–1.17)

2 (8.3)

1.00

1.05 (0.13–8.24)

27 (22.7)

0.11

0.47 (0.19–1.18)

2. L/M

20 (12.7)

23 (16.1)

0.27

0.60 (0.24–1.50)

7 (29.2)

0.26

0.30 (0.06–1.63)

16 (13.4)

0.64

0.79 (0.30–2.10)

3. M/M

9 (6.3)

8 (5.6)

0.67

0.77 (0.24–2.52)

1 (4.2)

1.00

0.95 (0.08–11.87)

7 (5.9)

0.74

0.81 (0.24–2.76)

4. H/L

45 (31.5)

33 (23.1)

0.87

0.93 (0.40–2.15)

4 (16.7)

1.00

1.18 (0.20–7.02)

29 (24.4)

0.96

0.98 (0.42–2.32)

5. H/M

29 (20.3)

30 (21.0)

0.35

0.66 (0.28–1.58)

8 (33.3)

0.30

0.38 (0.07–2.00)

22 (18.5)

0.70

0.83 (0.34–2.07)

6. H/H

19 (14.0)

13 (9.1)

-

-

2 (8.3)

-

-

12 (10.1)

-

-

7. Rare

15 (10.5)

7 (4.9)

0.51

0.68 (0.22–2.14)

0

0.50

-

6 (5.0)

0.45

0.63 (0.19–2.08)

8. H carrier (4 + 5 + 6)

93 (65.0)

76 (53.2)

-

-

14 (58.3)

-

-

63 (52.9)

-

-

9. L carrier (1 + 2 + 4)

85 (59.4)

85 (59.4)

0.35

1.22 (0.80–1.88)

13 (54.2)

0.97

1.02 (0.45–2.28)

72 (60.5)

0.33

1.25 (0.80–1.96)

10. other (1 + 2 + 3)

49 (31.2)

60 (41.6)

0.10

1.50 (0.92–2.43)

10 (41.7)

0.50

1.36 (0.56–3.28)

50 (42.0)

0.11

1.51 (0.91–2.50)

  1. CI confidence interval, EOPD early onset PD, LOPD late onset PD, OR odds ratio
  2. L low activity haplotype -A_C_C_G, M medium activity haplotype -A_T_C_A, H high activity haplotype -G_C_G_G; P values calculated in relation to each SNP normal genotype and allele frequency (rs6269 AA, allele A; rs4633 CC, allele C; rs4818 CC, allele C; rs4680 GG, allele G; rs4633-rs4680 CC/GG; rs6269-s4818 AA/CC) as a referent genotype; four SNPs: H/H (6) as a referent genotype [(1–5, 7), H carriers (8) as a referent genotype (9, 10); and L carriers (9) as a referent genotype (11). When more than 20% of the cell numbers were missing, or when the expected number of cases was less than 1.0 in a cell, Fisher’s exact test was performed. *P  0.05
Back to article page

Translational Neurodegeneration

ISSN: 2047-9158

Contact us